Von Willebrand factor (VWF) (VWF)

Von Willebrand factor (VWF) is a large, multimeric plasma glycoprotein essential for primary hemostasis (UniProt P04275). It functions as a molecular bridge between the vascular subendothelium and platelets by binding to collagen and the platelet glycoprotein Ib (GPIb) receptor, especially under high-shear conditions (PubMed: 25355110). Additionally, VWF serves as a critical carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation and delivering it to sites of vascular injury (StatPearls: Von Willebrand Disease). Deficiencies or qualitative defects in VWF lead to Von Willebrand disease, the most common inherited bleeding disorder, while the accumulation of ultra-large VWF multimers is a hallmark of thrombotic thrombocytopenic purpura (TTP) (NIH: Gene ID 7450). Therapeutic strategies include replacement with recombinant VWF (Vonicog alfa), stimulation of endogenous release via desmopressin, or the use of caplacizumab, a nanobody that inhibits the VWF-GPIb interaction to treat acquired TTP (FDA: Cablivi). Management of VWF-related disorders requires careful monitoring of VWF activity and antigen levels to balance the risks of hemorrhage and thrombosis.

Other names

VWFF8VWFvon Willebrand antigen IICoagulation factor VIII VWF

Therapeutic mechanisms include the replacement of deficient VWF protein, pharmacological stimulation of VWF release from endothelial storage sites (Weibel-Palade bodies), and the targeted inhibition of the VWF A1 domain to prevent its binding to platelet glycoprotein Ib-IX-V complexes.